Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?

Phase

N/A

Condition

Multiple Sclerosis

Hypogammaglobulinemia

Memory Loss

Treatment

Laboratory test

Clinical Study ID

NCT05357781

2021-02372

Ages 18-65
All Genders

Study Summary

The investigators hypothesize that hypogammaglobulinemia (defined as IgG serum concentration <7.0g/L) is a treatable cause of fatigue in people with MS:

The primary objective is to prove the link between hypogammaglobulinemia and fatigue in patients with multiple sclerosis.

The secondary objective is to show that fatigue is mediated via frequent infections in people with MS and hypogammaglobulinemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Diagnosis of Multiple Sclerosis following McDonald 2017-Criteria
Age 18-65 years
Stable MS disease at inclusion (definition: no clinical relapse, no MRI activity,stable disability within the last 12 months)
Unchanged immunotherapy within the last 12 months
Expanded Disability Status Scale (EDSS) level <4 points indicating fully ambulatorypatients.
Capability of written informed consent

Exclusion

Exclusion Criteria:

Severe depression (definition: Beck Depression Index-II (BDI-II) ≥29 points) orother established psychiatric diagnosis
Immunodeficiency other than hypogammaglobulinemia
Immunglobulin replacement therapy or indication for immunoglobulin replacementtherapy
Severe Sleepiness (definition: Epworth-Sleepiness-Scale (ESS) >16 points)
Fatigue aggravating factors such: liver/renal/thyroid dysfunction, substance abuse,medication (tranquilizers /antiepileptics/psychopharmaceuticals), chronic infectiousdisease (like hepatitis/HIV).
Other neurodegenerative/autoimmune disease.
Patients not able to give written consent
Vulnerable patients such as children, pregnant women and prisoners

Study Design

Laboratory test

July 01, 2022

December 30, 2026

Study Description

Multiple sclerosis (MS) is the most common cause of mental and physical disability in young adults affecting approximately 10'000-15'000 persons in Switzerland (incidence 16/100000; prevalence 190/100000). MS-fatigue affects at least 75% of the MS-patients (affected persons in Switzerland 7500-11250). MS-related fatigue has socioeconomic consequences leading to increased sick leaves and a higher probability of unemployment. Effective treatment strategies for MS-fatigue are missing, despite the appearance of more effective immunotherapies to treat autoimmune neuroinflammation and to control MS disease activity. The reason for the lack of therapeutic options is the unclear pathophysiological mechanism of fatigue with many non-MS associated influencing factors like thyroid dysfunction and anaemia.

Fatigue is also present in other inflammatory diseases, cancers and immunodeficiency syndromes. Regarding the latter patients with primary immunodeficiencies (PIDs) and common variable immunodeficiency (CVID) suffer from fatigue in 30 - 76%, which is more common than in the normal population. Studies investigating immunoglobulin replacement therapy in patients with CVID demonstrated a correlation between the frequency of infusions / s.c. applications and wear-off effect/fatigue.

Immunoglobulin deficiency seems to be much more common in people with autoimmune diseases. In MS reduced serum immunglobulin G (IgG) concentrations regardless of immunotherapy affect between 8 - 26% of the patients. Nonetheless consequences of IgG hypogammaglobulinemia in MS are partly unknown. However, based on the findings in patients with CVID, fatigue might be one of them. To close this knowledge gap prospective observational studies are needed.

Connect with a study center

University Hospital of Bern Inselspital
Bern, BE 3010
Switzerland
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.